Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Front Immunol ; 14: 1106837, 2023.
Artículo en Inglés | MEDLINE | ID: covidwho-2268541

RESUMEN

Introduction: Two doses of inactivated SARS-CoV-2 vaccine CoronaVac cannot elicit high efficacy against symptomatic COVID-19, especially against the Omicron variant, but that can be improved by a third dose in adults. The use of a third dose of CoronaVac in adolescents may be supported by immunobridging studies in the absence of efficacy data. Methods: With an immunobridging design, our study (NCT04800133) tested the non-inferiority of the binding and neutralizing antibodies and T cell responses induced by a third dose of CoronaVac in healthy adolescents (N=94, median age 14.2 years, 56% male) compared to adults (N=153, median age 48.1 years, 44% male). Responses against wild-type (WT) and BA.1 SARS-CoV-2 were compared in adolescents. Safety and reactogenicity were also monitored. Results: A homologous third dose of CoronaVac further enhanced antibody response in adolescents compared to just 2 doses. Adolescents mounted non-inferior antibody and T cell responses compared to adults. Although S IgG and neutralizing antibody responses to BA.1 were lower than to WT, they remained detectable in 96% and 86% of adolescents. T cell responses to peptide pools spanning only the mutations of BA.1 S, N and M in adolescents were preserved, increased, and halved compared to WT respectively. No safety concerns were identified. Discussion: The primary vaccination series of inactivated SARS-CoV-2 vaccines for adolescents should include 3 doses for improved humoral immunogenicity.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Adulto , Adolescente , Masculino , Humanos , Persona de Mediana Edad , Femenino , SARS-CoV-2 , COVID-19/prevención & control , Anticuerpos Neutralizantes
2.
Nat Commun ; 13(1): 3700, 2022 06 28.
Artículo en Inglés | MEDLINE | ID: covidwho-1908180

RESUMEN

We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of 2-dose BNT162b2 and CoronaVac in healthy adolescents as primary objectives. One-dose BNT162b2, recommended in some localities for risk reduction of myocarditis, is also assessed. Antibodies and T cell immune responses are non-inferior or similar in adolescents receiving 2 doses of BNT162b2 (BB, N = 116) and CoronaVac (CC, N = 123) versus adults after 2 doses of the same vaccine (BB, N = 147; CC, N = 141) but not in adolescents after 1-dose BNT162b2 (B, N = 116). CC induces SARS-CoV-2 N and N C-terminal domain seropositivity in a higher proportion of adolescents than adults. Adverse reactions are mostly mild for both vaccines and more frequent for BNT162b2. We find higher S, neutralising, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC, and a similar induction of strong S-specific T cells by the 2 vaccines, in addition to N- and M-specific T cells induced by CoronaVac but not BNT162b2, possibly implying differential durability and cross-variant protection by BNT162b2 and CoronaVac, the 2 most used SARS-CoV-2 vaccines worldwide. Our results support the use of both vaccines in adolescents.


Asunto(s)
COVID-19 , Vacunas Virales , Adolescente , Adulto , Vacuna BNT162 , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , Humanos , SARS-CoV-2
3.
Front Immunol ; 12: 797919, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1608316

RESUMEN

Persistence of protective immunity for SARS-CoV-2 is important against reinfection. Knowledge on SARS-CoV-2 immunity in pediatric patients is currently lacking. We opted to assess the SARS-CoV-2 adaptive immunity in recovered children and adolescents, addressing the pediatrics specific immunity towards COVID-19. Two independent assays were performed to investigate humoral and cellular immunological memory in pediatric convalescent COVID-19 patients. Specifically, RBD IgG, CD4+, and CD8+ T cell responses were identified and quantified in recovered children and adolescents. SARS-CoV-2-specific RBD IgG detected in recovered patients had a half-life of 121.6 days and estimated duration of 7.9 months compared with baseline levels in controls. The specific T cell response was shown to be independent of days after diagnosis. Both CD4+ and CD8+ T cells showed robust responses not only to spike (S) peptides (a main target of vaccine platforms) but were also similarly activated when stimulated by membrane (M) and nuclear (N) peptides. Importantly, we found the differences in the adaptive responses were correlated with the age of the recovered patients. The CD4+ T cell response to SARS-CoV-2 S peptide in children aged <12 years correlated with higher SARS-CoV-2 RBD IgG levels, suggesting the importance of a T cell-dependent humoral response in younger children under 12 years. Both cellular and humoral immunity against SARS-CoV-2 infections can be induced in pediatric patients. Our important findings provide fundamental knowledge on the immune memory responses to SARS-CoV-2 in recovered pediatric patients.


Asunto(s)
Inmunidad Adaptativa/inmunología , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , COVID-19/inmunología , Convalecencia , SARS-CoV-2/inmunología , Adolescente , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Linfocitos T CD4-Positivos/virología , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/metabolismo , Linfocitos T CD8-positivos/virología , COVID-19/virología , Niño , Preescolar , Femenino , Humanos , Inmunidad Humoral/inmunología , Inmunoglobulina G/inmunología , Masculino , SARS-CoV-2/metabolismo , SARS-CoV-2/fisiología , Glicoproteína de la Espiga del Coronavirus/inmunología , Glicoproteína de la Espiga del Coronavirus/metabolismo
4.
Mol Biomed ; 1(1): 8, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-1515456
5.
Inf Process Manag ; 58(6): 102731, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: covidwho-1370552

RESUMEN

The development of the Internet and social media has expanded the speed and scope of information dissemination, but not all widely disseminated information is true. Especially during the public health emergencies, the endogenous health information demand generated by the lack of scientific knowledge of health information among online users stimulates the dissemination of health information by mass media while providing opportunities for rumor mongers to publish and spread online rumors. Invalid scientific knowledge and rumors will have a serious negative impact and disrupt social order during epidemic outbreaks such as COVID-19. Therefore, it is extremely important to construct an effective online rumor reversal model. The purpose of this study is to build an online rumor reversal model to control the spread of online rumors and reduce their negative impact. From the perspective of internal and external factors, based on the SIR model, this study constructed a G-SCNDR online rumor reversal model by adopting scientific knowledge level theory and an external online rumor control strategy. In this study, the G-SCNDR model is simulated, and a sensitivity analysis of the important parameters of the model is performed. The reversal efficiency of the G-SCNDR model can be improved by properly adopting the isolation-conversion strategy as the external control approach to online rumors with improving the popularization rate of the level of users' scientific knowledge and accelerating the transformation efficiency of official nodes. This study can help provide a better understanding of the process of online rumor spreading and reversing, as well as offering ceritain guidance and countermeasures for online rumor control during public health emergencies.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA